Overexpression of SphK/S1P signaling is often associated with cancer drug resistance to chemotherapy, radiation therapy, or hormonal therapies in various types of cancers, including breast, prostate, multiple myeloma, and pancreatic cancers [3, 25, 46, 47, 72, 74–77]. Here, MBTPS1 is linked to cancer.